VIZIMPRO, with the active ingredient dacomitinib, is a prescription medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). Specifically, it is designed for patients whose tumors have specific genetic mutations in the epidermal growth factor receptor (EGFR) gene. VIZIMPRO works as a tyrosine kinase inhibitor, a class of drugs that blocks the action of enzymes known as tyrosine kinases, which are involved in the growth and spread of cancer cells. By inhibiting these enzymes, VIZIMPRO can help slow down or stop the progression of the cancer. It is typically prescribed after other treatments have failed and is taken orally in tablet form. As with any cancer medication, it comes with a range of potential side effects, and its use should be closely monitored by a healthcare professional.